Casale TB, et al. - In patients with the eosinophilic phenotype, blocking the interaction of interleukin (IL)-5 with its receptor on eosinophils lessens asthma symptoms, so researchers carried out a systematic literature review and network meta-analysis to perform an indirect comparison between reslizumab, which binds to IL-5, and benralizumab, which targets the IL-5 receptor α subunit, in similar patient populations. According to findings, reslizumab could be more effective in patients with eosinophilic asthma in Global Initiative for Asthma step 4/5 with elevated blood eosinophil levels (benralizumab, ≥300/μL; reslizumab, ≥400/μL) and ≥2 exacerbations in the previous year.